Back
75· Active
Health & Science1d 8h ago
The FDA’s Oncologic Drugs Advisory Committee voted unanimously in favor of the safety and efficacy of vorasidenib for patients with IDH-mutant gliomas.
Silver Spring, Maryland, USA
Who
FDA Advisory Committee / Servier Pharmaceuticals
What
The FDA’s Oncologic Drugs Advisory Committee voted unanimously in favor of the safety and efficacy of vorasidenib for patients with IDH-mutant gliomas.
When
Mon, 08 Jun 2026 01:50:05 GMT · 1d 8h ago
Where
Silver Spring, Maryland, USA · 39.00°N, 77.03°W
Why
Clinical trial data demonstrated that the drug significantly delayed tumor progression, offering a non-invasive alternative to chemotherapy or radiation.
The Frontline Impact
How this affects you
This signals a major shift in brain cancer management, potentially allowing patients to delay more aggressive treatments like radiation for years while maintaining quality of life.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.